Research

Hormonal

Inpatient administration of GLP-1 receptor agonists (liraglutide and semaglutide) combined with a very low-calorie diet (800 kcal/day) produces rapid, substantial weight loss (25% of baseline) in severely obese patients (BMI > 100 kg/m2) who are hospitalized.

For severely obese patients (BMI > 100) who struggle with discharge or outpatient adherence, inpatient GLP-1RA therapy combined with a strict 800 kcal/day diet can produce rapid, substantial weight loss (approx. 25% in <8 months). This approach may serve as a bridge to bariatric surgery or functional independence when standard outpatient care fails due to socioeconomic or medical barriers.

WeakSupportsLOW confidence
The patient lost a total of 174 lbs (79 kg) from the start of the GLP-1RA therapy until week 31... The patient’s weight decreased by 174 lbs (79 kg), or 25% of baseline weight, and BMI decreased from 108 to 81 kg/m2.
Yaiseli Figueredo et al. · Cureus · 2023

Why this rating

This is a single case report (n=1), which provides low generalizability despite the dramatic result.

Source

Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission

Yaiseli Figueredo et al. · Cureus · 2023

DOI 10.7759/cureus.34331

case_report · n=1Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →